Baxter International Inc. — Wall Street Analyst Estimates & Price Targets

BAX

NYSEHealthcareMedical - Instruments & SuppliesCIK 0000010456baxter.comAbout BAX

Last close · Oct 16, 202625.28−0.48 (−1.86%)

Market cap$13.1B

3 firms' latest targets, last 90 days: median $25.00 ($20.00–$28.00), 1% below the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 3 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-06	Barclays	$20.00	$27.00	▼ 26%	-18%	-21%
2026-07-31	Stifel	$28.00	$24.00	▲ 17%	+5%	+11%
2026-07-28	UBS	$25.00	$19.00	▲ 32%	+2%	-1%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2021reported	$12.8B	+10%	$2.53	+19%	est. $12.6B+2%	est. $3.60	4
2022reported	$15.1B	+18%	-$4.83	-291%	est. $15.0B+1%	est. $3.56	3
2023reported	$14.8B	-2%	$5.25	—	est. $14.7B+0%	est. $2.59	9
2024reported	$10.6B	-28%	-$1.27	-124%	est. $10.6B+1%	est. $1.84	9
2025reported	$11.2B	+6%	-$1.87	—	est. $11.1B+1%	est. $2.37	10
2026	$11.6B	+3%	$2.05	-13%	$11.6B–$11.6B	$1.98–$2.08	10
2027	$11.9B	+2%	$2.04	+0%	$11.8B–$11.9B	$1.71–$2.17	10
2028	$12.1B	+2%	$2.17	+6%	$12.0B–$12.3B	$1.44–$3.10	7

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$25.00median target, 1% below the last close

Firms with a target · last 90 days: 3
Lowest – highest target: $20.00 – $28.00
Current grades of 10 firms: positive / neutral / negative: 2 / 7 / 1
Upgrades / downgrades · 12 months: 1 / 2
Consensus revenue growth · next 3 FY: +3% a year

Current grades

each firm's latest · 10 firms

As of	Firm	Grade
2026-10-05	Citigroup	“Neutral”
2026-07-31	Wells Fargo	“Equal Weight”
2026-07-31	TD Cowen	“Hold”
2026-07-31	Stifel	“Hold”
2026-07-28	UBS	“Neutral”
2026-07-15	Goldman Sachs	“Neutral”
2026-07-06	Evercore ISI	“Outperform”
2026-05-04	Barclays	“Overweight”
2025-12-02	Morgan Stanley	“Underweight”
2025-10-31	Argus Research	“Hold”

Grade changes

last 24 months · 4

Date	Firm	Grade
2026-07-31	Citigroup	“Sell” → “Neutral” upgrade
2026-05-28	Citigroup	“Neutral” → “Sell” downgrade
2025-10-31	Argus Research	“Buy” → “Hold” downgrade
2025-08-04	Stifel	“Buy” → “Hold” downgrade

47 older than 24 months

2024-07-15	Morgan Stanley	“Equal Weight” → “Underweight” downgrade
2024-05-10	TD Cowen	“Buy” → “Hold” downgrade
2023-01-06	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2023-01-05	Raymond James	“Outperform” → “Market Perform” downgrade
2023-01-03	Bank of America	“Buy” → “Neutral” downgrade
2022-12-19	J.P. Morgan	“Overweight” → “Neutral” downgrade
2022-12-15	Deutsche Bank	“Buy” → “Hold” downgrade
2022-12-12	Citigroup	“Buy” → “Neutral” downgrade
2022-06-24	Wells Fargo	“Overweight” → “Equal Weight” downgrade
2022-04-04	Goldman Sachs	“Neutral” → “Sell” downgrade
2022-01-07	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2021-09-13	TD Cowen	“Market Perform” → “Outperform” upgrade
2021-09-03	Barclays	“Equal Weight” → “Overweight” upgrade
2021-01-29	Piper Sandler	“Overweight” → “Neutral” downgrade
2020-10-01	Citigroup	“Neutral” → “Buy” upgrade
2020-09-04	Argus Research	“Buy” → “Hold” downgrade
2020-03-19	Stifel	“Hold” → “Buy” upgrade
2020-03-18	KeyBanc	“Sector Weight” → “Overweight” upgrade
2020-01-02	Evercore ISI	“In Line” → “Outperform” upgrade
2019-12-17	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2019-06-26	KeyBanc	“Sector Weight” → “Equal Weight” revised
2019-04-08	Evercore ISI	“Outperform” → “In Line” downgrade
2019-02-01	Barclays	“Underweight” → “Equal Weight” upgrade
2019-01-02	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2019-01-02	Citigroup	“Neutral” → “Buy” upgrade
2018-11-02	Argus Research	“Hold” → “Buy” upgrade
2018-01-03	Raymond James	“Market Perform” → “Outperform” upgrade
2018-01-02	Bank of America	“Neutral” → “Buy” upgrade
2018-01-02	J.P. Morgan	“Neutral” → “Overweight” upgrade
2017-07-11	BMO Capital	“Market Perform” → “Outperform” upgrade
2016-04-14	Piper Sandler	“Neutral” → “Overweight” upgrade
2015-07-30	Leerink Partners	“Outperform” → “Market Perform” downgrade
2015-07-07	BMO Capital	“Outperform” → “Market Perform” downgrade
2015-07-02	Bank of America	“Buy” → “Neutral” downgrade
2015-06-30	Credit Suisse	“Outperform” → “Neutral” downgrade
2014-01-07	RBC Capital	“Outperform” → “Sector Perform” downgrade
2013-11-18	Credit Suisse	“Neutral” → “Outperform” upgrade
2013-10-23	TD Cowen	“Outperform” → “Market Perform” downgrade
2013-10-18	Raymond James	“Outperform” → “Market Perform” downgrade
2013-10-18	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2013-10-02	Credit Suisse	“Outperform” → “Neutral” downgrade
2013-09-04	C.L. King	“Neutral” → “Buy” upgrade
2013-05-07	Barclays	“Equal Weight” → “Overweight” upgrade
2012-11-27	Mizuho	“Buy” → “Neutral” downgrade
2012-09-24	Deutsche Bank	“Buy” → “Hold” downgrade
2012-02-24	Citigroup	“Sell” → “Neutral” upgrade
2012-02-16	Standpoint Research	“Buy” → “Hold” downgrade

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.